Program Overview 2024
Expand your knowledge on finance & valuation in Life Sciences & Health
| Module | Topics | Teachers | Content | |
| Module 1. 1 November 2024 The basics of strategic funding: market trends and financial statement analysis | Course introduction | Linda van de Burgwal / Kenneth Fernald | Introduction to the Finance for Growth course | |
| Setting
the scene for biopharma strategic funding: market trends, drivers &
opportunities | Eric Claassen | Explain why the
biopharma market differs from traditional markets in terms of financing | ||
| Financial statement analysis | Marc Schauten / Arjen Siegmann | What to learn from
financial statements? The basics of reading and interpreting balance sheets,
profit and loss statements and cash flow statements | ||
| Module 2. 8 November 2024 | Discounted cash flow analysis | Marc Schauten / Arjen Siegmann | Conducting smart calculations with a common spreadsheet tool: advanced use of Excel functions | |
| Venture capital deal terms | Harm de Vries | What to look for when negotiating with venture capital? The most often used venture capital deal terms and the most overlooked clauses. | ||
| Module 3. 15 November 2024 | Investment
risk and the cost of capital | Marc Schauten / Arjen Siegmann | Why the profits in
pharma need to be high, or: the time value of money and capital budgeting | |
| Non-dilutive funding | Judith Smit | How do I finance a business? Applying the dilutive and non-dilutive funding mix to finance life sciences ventures | ||
| Module 4. 22 November 2024 The impact of risk and return: cost of capital and valuation by VCs | Introduction to options | Marc Schauten / Arjen Siegmann | To understand optionality this lecture introduces financial options. They provide the intuition and the machinery to deal with real options. | |
| Valuation by VCs | Bart Bergstein | How do venture
capitalists valuate companies before they invest? Experiences from a seasoned
investor. | ||
| Module 5. 29 November 2024 Valuating your company: valuation approach and industry specific margins | Valuation
techniques for the firm | Matteo Millone | How to
determine the value of a company | |
| How to scale-up sensibly | Pieter Wijffels | How to
balance R&D with sales & marketing in the life sciences industry | ||
| Industry specific costs, revenues, margins and risk profiling | Eric Claassen | How to
conduct financial calculations for the Life Sciences: industry specific costs,
revenues, margins and risk profiling | ||
| Module 6. 6 December 2024 Securing an exit: perspectives of investment bankers and valuation of M&A deals | Real options | Marc Schauten / Arjen Siegmann | When it might be better to wait. Using real options in the biopharma sector. | |
| VC investment and exit patterns and Valuation methods | Kenneth Fernald | Venture Capital Investments and exits in biotech/pharma; and Valuation: DCF and rNPV methods | ||
| Valuation by investment
bankers | Van Lanschot-Kempen (Robert-Jan and Tom) | How do
investment bankers valuate companies in order to get to an exit? A real-life
example. | ||
| Module 7. 13 December 2024 Get active: understanding and applying 24 financing modalities while optimizing your company’s position | The innovators perspective | Yves Prevoo | The role of budget impact and incremental cost-effectiveness | |
| Crowdfunding in Life Sciences | Simon Douw | When standard financing modalities are not enough. The use of crowdfunding in health and life sciences | ||
| Financing
modalities for the firm | Eric Claassen | Understanding and applying over 24 financing modalities for your firm (emphasis on non-dilutive instruments) |
Faculty / Speakers
Linda van de Burgwal
VU
Eric Claassen
VU
Judith Smith
FFUND
Harm de Vries
Innovation Industries
| Powered by: Hyphen Projects | Connect with us | ||
| Privacy Policy Terms and conditions Chamber of Commerce: 32110979 | |
| © Copyright 2021 by Hyphen Projects |